BOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.
Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentation.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
Investor Contact:
Kellen Sanger
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Kelly Katapodis
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.83 |
Daily Change: | 0.02 0.71 |
Daily Volume: | 19,162 |
Market Cap: | US$188.030M |
January 28, 2025 November 06, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load